Asia-Pacific Autoimmune Disease Diagnostics Market Growth, Trends and Forecasts 2017 - 2022

  • ID: 4387317
  • Report
  • 107 pages
  • Mordor Intelligence
1 of 3
Asia-Pacific Autoimmune disease diagnostics Market has been estimated at USD 1.152 billion in 2014 and is projected to reach USD 2.002 billion in 2020 at a CAGR of 11.7% during the forecast period from 2014 to 2021. Autoimmune diseases occur as a result of abnormal immune response of the body against healthy body tissues. This diseases are more prevalent in women. Autoimmune diseases diagnostics are used for detection of the type and stage of autoimmune disease. The autoimmune diseases include type 1 diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), rheumatoid arthritis, inflammatory bowel disease, psoriasis, uveitis and autoimmune thyroid disease.

This market has wide applications in consultation & diagnosis, therapy & monitoring and drug discovery & development areas. Hospitals, clinical diagnostics labs, pharmaceutical industries and CROs are the end users of this market.

Increased incidence of chronic autoimmune diseases, increasing disease awareness and improved laboratory automation are the key driving factors for the market. In addition, rising government initiatives trigger the growth of this market. However, High frequency of false positive results and shortage of skilled technicians also limits the market growth.

Asia-Pacific autoimmune disease diagnostic market is segmented by types i.e. Localized autoimmune disease diagnostics and Systemic Autoimmune disease diagnostics, by test which includes antinuclear antibody test, autoantibody test, complete blood count, comprehensive metabolic panel, C-reactive protein test, erythrocyte sedimentation rate, urinalysis and others. On basis of disease, the market is categorized into type 1 diabetes, Graves‰Ûª disease, Hashimotosthyroiditis, multiple sclerosis, systemic lupus erythematosus (SLE), rheumatoid arthritis, inflammatory bowel disease, psoriasis, uveitis and autoimmune thyroid disease.

Geographically, Asia-Pacific autoimmune disease diagnostics market has been segmented into India, China, Japan, Australia, New Zealand and South Korea. Asia-Pacific shows a high growth potential because of increasing population of people suffering from autoimmune diseases. The market is expected to grow at the fastest rate due to presence of unmet medical needs, and increasing per capita healthcare expenditure. Asian American women experience Rheumatoid arthritis at a rate higher than the general population. Likewise, lupus is more common in woman of Asian origin as compared to women of other region, propelling the market for autoimmune disease diagnostic market to grow. Improving healthcare infrastructure and patient awareness levels in the emerging markets of India and China drive contribute well to the revenues of Asia-Pacific market.

Many players in this market are trying to expand their product portfolio in order to top the global market. While few companies are entering into the market by acquisitions, top companies are expanding their growth in this market by acquiring other companies. Few companies adopted product innovation and new product launches as its key business strategy to ensure its dominance in this market. Major companies discussed in the report are Roche, Abbott Laboratories, Bayer Healthcare, Biogen, Eli Lilly, Quest Diagnostics and GlaxoSmithKline.

Key Deliverables:

Market analysis for the Asia-Pacific autoimmune disease diagnostics Market, with region specific assessments and competition analysis on global and regional scales

Market definition along with the identification of key drivers and restraints

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale

Extensively researched competitive landscape section with profiles of major companies along with their market shares

Identification and analysis of the macro and micro factors that affect the Asia-Pacific autoimmune disease diagnostics Market on both global and regional scales

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1.Introduction
2.Executive Summary
3.Market Overview
3.1 Asia-Pacific Autoimmune Disease Diagnostic Market
3.2 Trends and Forecast
3.3 Market Size and Share Estimation
3.4 Key Products and Services in Market
3.5 Technologies In Asia-Pacific Autoimmune disease diagnostic market
4.Market Dynamics
4.1 Market Drivers
4.1.1 Growing Public awareness of autoimmune disease
4.1.2 Expansion in Coverage Allowed by Patient Protection and Affordable Care Act
4.1.3 Improved Laboratory Automation
4.1.4 Partnerships with Physicians and Clinical Laboratories
4.2 Market Restraints
4.2.1 Slow turnaround Time for Autoimmune Disease Diagnostic Test Results
4.2.2 High Frequency of False Positive Results
4.2.3 Lacking Automation and Shortage of Skilled Technicians
4.2.4 Relatively low prevalence of Localized Autoimmune Diseases.
5. Asia-Pacific Autoimmune Disease Market Diagnosis
5.1 Identification of human autoantibodies
5.2 Techniques and methods used for the detection of antibodies
5.2.1 Immunofluorescence
5.2.2 Enzyme immunoassay
5.2.3 Multiplexed immunoassays
5.2.4 Microarray based assays
5.2.5 Bead-based assay
5.2.6 Proteomictechnologies for the study and diagnosis of autoimmune diseases
6.MARKET SEGMENTATION
6.1 Asia-Pacific Autoimmune Disease Market Diagnosis Segmentation, By Types
6.1.1 Localized Autoimmune Disease Diagnostics Segment
6.1.1.1 Forecasts and Trends
6.1.1.2 Market Share and Competitive Analysis
6.1.1.3 Multiple Sclerosis
6.1.1.4 Inflammatory Bowel Disease
6.1.1.5 Type I Diabetes
6.1.1.6 Thyroid
6.1.2 Systemic Autoimmune Disease Diagnostics Segment
6.1.2.1 Forecasts and Trends
6.1.2.2 Market Share and Competitive Analysis
6.1.2.3 Rheumatoid Arthritis
6.1.2.4 Psoriasis
6.1.2.5 Lupus
6.2 Asia-Pacific Autoimmune Disease Market Diagnosis Segmentation, By Products
6.2.1 Drugs
6.2.2 Therapeutic and Monitoring Equipments
6.2.3 Diagnostic Equipments
6.3 Asia-Pacific Autoimmune Disease Market Diagnosis Segmentation, By Service Market
6.3.1 Consultation & Diagnosis
6.3.2 Therapy & Monitoring
6.3.3 Drug Development and Discovery
6.4 Asia-Pacific Autoimmune Disease Market Diagnosis Segmentation, By Technology
6.4.1 DMARD (disease-modifying anti-rheumatic drugs) and biologic DMARD therapy
6.4.2 Bridge therapy
6.4.3 Topical therapy
6.4.4 Phototherapy
6.4.5 Helminthic therapy
6.4.6 Fecalbacteriotherapy
6.4.7 Haematopoietic stem-cell transplantation
6.4.8 Recombinant technology
6.5 Asia-Pacific Autoimmune Disease Market Diagnosis Segmentation, By Geography
6.5.1 Asia-Pacific
6.5.1.1 Japan
6.5.1.2 Australia
6.5.1.3 China
6.5.1.4 India
6.5.1.5 Malaysia
6.5.1.6 Singapore
7. Competitive Landscape
7.1 New Product Launch
7.2 Market Share Analysis by Key Players
7.3 Mergers & Acquisitions
7.4 Market Share Analysis
8. Company profiles
8.1 Roche
8.2 Abbott Autoimmune Inc.
8.3 Bayer-Schering Pharmaceuticals
8.4 Biogen Idec
8.5 Eli Lilly
8.6 GlaxosmithKline
9. Appendix
9.1. Abbreviations
9.2. Sources
9.3. Bibliography
9.4. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll